|
|
 |
Ryan Haumschild, PharmD, MS, MBA, CPEL |
|
|
 |
Michael Kobernick, MD, MS, MS-PopH, CPE |
|
|
 |
Hans Lee, MD |
|
|
 |
Sita Bhatt, PharmD, BCOP |
|
|
 |
Yvette D. |
|
|
Managed Care Review Board™ Presents:
Managed Care Strategies to Optimize Overall Outcomes in Multiple Myeloma
|
||||||||||||||||||||||
| Expert Faculty Presenters: | ||||||||||||||||||||||
|
||||||||||||||||||||||
Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Statement of Need/Program Overview
Managed care and payer professionals will receive knowledge and skills to implement and/or recommend evidence-based oncology coverage and reimbursement policy that is based on current clinical practice guidelines, the rationale for the use of various agents, and the myriad of factors that must be weighed in treatment selection for RRMM. In addition, managed care and payer professionals can benefit by leveraging the full potential of multidisciplinary care in the optimal management of RRMM.
Educational Objectives
After completing this activity, the participant should be better able to:
Accreditation Information
 |
Joint Accreditation Statement |
Physician Continuing Medical Education
Medical Education Resources designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Credit
Medical Education Resources designates this enduring material for a maximum of 1.25 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.25 contact hours.
Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
UAN: JA0003680-9999-25-044-H01-P
Type of Activity: Knowledge-based
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.
The authors reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:
| Name of Faculty | Reported Financial Relationship |
|---|---|
| Ryan Haumschild, PharmD, MS, MBA, CPEL | Nothing to disclose |
| Michael Kobernick, MD, MS, MS-PopH, CPE | Nothing to disclose |
| Hans Lee, MD | Grants/Research Support - Amgen, Bristol Myers Squibb, Janssen, GlaxoSmithSkine, Regeneron, Takeda Pharmaceuticals Consulting fees (eg. Ad Boards) - Bristol Myers Squibb, Pfizer, Janssen, Regeneron, GlaxoSmithKline, Sanofi, Abbvie, Takeda Pharmaceuticals, Allogene Therapeutics |
| Sita Bhatt, PharmD, BCOP | Nothing to disclose |
| Yvette D. | Nothing to disclose |
The content managers reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:
| Name of Content Managers | Reported Financial Relationship |
|---|---|
| Impact Education, LLC. | No financial relationships to disclose |
| Planners at Medical Education Resources | No financial relationships to disclose |
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Regeneron Pharmaceuticals, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
FEE INFORMATION
There is no fee for this educational activity.